Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to
radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors. This
study is also being done to find out the highest doses of copanlisib and vemurafenib that,
when given in combination, do not cause serious side effects, and whether the study treatment
will make radioiodine therapy work better in patients with BRAF-mutant thyroid cancers.